This was the first large randomized trial to show a cardiovascular mortality benefit from a weight loss drug in non-diabetic patients, and it significantly expanded the clinical case for semaglutide beyond metabolic endpoints
In this comprehensive comparison provided by Reliable MD, a trusted medical institution in Sarasota, FL, we delve into the unique characteristics, effectiveness, and possible side effects of each drug, helping patients make an informed decision about their health
145 Ractigen Therapeutics has submitted an Investigational New Drug application for RAG-01, and it is expected to become the second saRNA drug to enter clinical trials internationally
Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo
Annual or Preventive Screening In preventive or executive health settings, an annual EKG may be included to catch silent abnormalities before symptoms develop
